ALT - Altimmune, Inc.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
1.69
+0.06 (+3.68%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.63
Open1.62
Bid0.00 x 0
Ask0.00 x 0
Day's Range1.51 - 1.84
52 Week Range0.02 - 12.85
Volume984,438
Avg. Volume134,573
Market Cap26.41M
Beta1.03
PE Ratio (TTM)N/A
EPS (TTM)-3.37
Earnings DateN/A
Forward Dividend & Yield0.00 (0.00%)
Ex-Dividend Date2017-01-20
1y Target Est6.00
Trade prices are not sourced from all markets
  • Capital Cube3 days ago

    ETFs with exposure to Altimmune, Inc. : December 11, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Altimmune, Inc. Here are 5 ETFs with the largest exposure to ALT-US. Comparing the performance and risk of Altimmune, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • GlobeNewswire3 days ago

    Altimmune Submits Investigational New Drug Application for NasoShield in Preparation for its Phase 1 Trial

    145 Patients to be enrolled Data expected in the second quarter of 2018 Study will be fully-funded by BARDA. GAITHERSBURG, Md., Dec. 11, 2017-- Altimmune, Inc., a clinical-stage immunotherapeutics company, ...

  • Capital Cube14 days ago

    ETFs with exposure to Altimmune, Inc. : November 30, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Altimmune, Inc. Here are 5 ETFs with the largest exposure to ALT-US. Comparing the performance and risk of Altimmune, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • GlobeNewswire23 days ago

    Altimmune to Present at the 29th Annual Piper Jaffray Conference

    GAITHERSBURG, Md., Nov. 21, 2017-- Altimmune, Inc., a clinical-stage immunotherapeutics company, today announced that Bill Enright, president and chief executive officer of Altimmune, will present a corporate ...

  • Capital Cube24 days ago

    ETFs with exposure to Altimmune, Inc. : November 20, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Altimmune, Inc. Here are 5 ETFs with the largest exposure to ALT-US. Comparing the performance and risk of Altimmune, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Altimmune, Inc. :ALT-US: Earnings Analysis: Q3, 2017 By the Numbers : November 17, 2017
    Capital Cube27 days ago

    Altimmune, Inc. :ALT-US: Earnings Analysis: Q3, 2017 By the Numbers : November 17, 2017

    Categories: Yahoo FinanceGet free summary analysis Altimmune, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Altimmune, Inc. – Emergent BioSolutions Inc., Pfizer Inc., Dynavax Technologies Corporation, Baxter International Inc., Soligenix, Inc., Johnson & Johnson and XOMA Corporation (EBS-US, PFE-US, DVAX-US, BAX-US, SNGX-US, JNJ-US and ... Read more (Read more...)

  • GlobeNewswirelast month

    Altimmune Announces Third Quarter 2017 Financial Results and Provides Corporate Update

    Initiated a Phase 2 clinical trial with NasoVAX vaccine with initial data expected in first quarter 2018. Completed enrollment in its Phase 1 HepTcell clinical trial with data expected in fourth quarter ...

  • GlobeNewswirelast month

    Altimmune to Announce Third Quarter 2017 Financial Results on November 9

    GAITHERSBURG, Md., Nov. 02, 2017-- Altimmune, Inc., a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the three and nine months ended September 30, ...

  • Capital Cube2 months ago

    ETFs with exposure to Altimmune, Inc. : October 25, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Altimmune, Inc. Here are 5 ETFs with the largest exposure to ALT-US. Comparing the performance and risk of Altimmune, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • What’s Ahead For Altimmune Inc (ALT)?
    Simply Wall St.3 months ago

    What’s Ahead For Altimmune Inc (ALT)?

    Altimmune Inc (NASDAQ:ALT), a USD$39.79M small-cap, operates in the healthcare industry, which has experienced tailwinds from issues such as higher demand driven by an aging population and the increasing prevalenceRead More...

  • GlobeNewswire3 months ago

    Altimmune Announces its Phase 2 Flu Vaccine Trial with NasoVAX Open for Enrollment

    60 Patients to be enrolled Data expected in the first quarter of 2018. GAITHERSBURG, Md., Sept. 20, 2017-- Altimmune, Inc., a clinical-stage immunotherapeutics company, today announced that they have been ...

  • GlobeNewswire3 months ago

    Altimmune to Provide Corporate Update at the Ladenburg Thalmann 3rd Annual Healthcare Conference

    GAITHERSBURG, Md., Sept. 19, 2017-- Altimmune, Inc., a clinical-stage immunotherapeutics company, today announced that Bill Enright, President and Chief Executive Officer of Altimmune, will present a corporate ...

  • Capital Cube4 months ago

    ETFs with exposure to Altimmune, Inc. : August 25, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Altimmune, Inc. Here are 5 ETFs with the largest exposure to ALT-US. Comparing the performance and risk of Altimmune, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Altimmune, Inc. :ALT-US: Earnings Analysis: Q2, 2017 By the Numbers : August 17, 2017
    Capital Cube4 months ago

    Altimmune, Inc. :ALT-US: Earnings Analysis: Q2, 2017 By the Numbers : August 17, 2017

    Categories: Yahoo FinanceGet free summary analysis Altimmune, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Altimmune, Inc. – Emergent BioSolutions Inc., Pfizer Inc., Dynavax Technologies Corporation, Baxter International Inc., Soligenix, Inc., Cempra, Inc., Johnson & Johnson and XOMA Corporation (EBS-US, PFE-US, DVAX-US, BAX-US, SNGX-US, ... Read more (Read more...)

  • Capital Cube5 months ago

    ETFs with exposure to Altimmune, Inc. : July 11, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Altimmune, Inc. Here are 5 ETFs with the largest exposure to ALT-US. Comparing the performance and risk of Altimmune, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube6 months ago

    ETFs with exposure to Altimmune, Inc. : June 16, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Altimmune, Inc. Here are 5 ETFs with the largest exposure to ALT-US. Comparing the performance and risk of Altimmune, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)